In summary, targeting HDAC2 and its modulation of SmD2 acetylation and expression represents a promising strategy for inhibiting HCC progression, with Romidepsin emerging as an effective therapeutic option. This evidence concerns the gene HDAC2 and hepatocellular carcinoma.